Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies

Official Title

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

Summary:

The primary objective of this study is to characterize the safety, tolerability and maximum tolerated dose of BMS-986016 administered alone or in combination with Nivolumab to subjects with relapsed hematologic malignancies. Co-primary objective is to investigate the preliminary efficacy of BMS-986016 in combination with nivolumab in subjects with relapsed or refractory Hodgkin lymphoma (HL), and relapsed or refractory Diffuse Large B Cell lymphoma (DLBCL)

Trial Description

Primary Outcome:

  • Proportion of subjects with Adverse Events (AEs)
  • Proportion of subjects with Serious Adverse Events (SAEs)
  • Proportion of Deaths
  • Proportion of subjects with clinical laboratory test abnormalities
  • Objective response rate (ORR)
  • Duration of Response (DOR)
Secondary Outcome:
  • Maximum observed serum concentration (Cmax) of BMS-986016 administered alone and in combination with Nivolumab
  • Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with Nivolumab
  • Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with Nivolumab
  • Concentration at the end of a dosing interval (Ctau) of BMS-986016 administered both alone and in combination with Nivolumab
  • Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016 administered both alone and in combination with Nivolumab
  • Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986016 administered both alone and in combination with Nivolumab
  • Total body clearance (CLT) of BMS-986016 administered both alone alone and in combination with Nivolumab
  • Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with Nivolumab
  • Effective elimination half-life that explains the degree of AUC administered alone accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with Nivolumab
  • Effective elimination half-life that explains the degree of Cmax administered alone accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with Nivolumab
  • Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with Nivolumab
  • Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with Nivolumab
  • Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with Nivolumab
  • Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016 administered both alone and in combination with Nivolumab
  • Incidence of ADA to nivolumab and BMS-986016
  • Summary of AEs of special interest by

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society